摘要
目的 定量分析初诊慢性B淋巴细胞白血病（B-CLL）患者外周血单个核细胞和血浆中增殖诱导配体（APRIL）mRNA及蛋白的表达水平并分析其临床意义.方法 采用实时荧光定量聚合酶链反应（RFQ-PCR）及酶联免疫吸附试验（ELISA）方法,检测32例B-CLL患者及15名健康对照靶基因及靶蛋白含量.结果 RFQ-PCR检测APRIL mRNA含量,批内和批间重复性测定的变异系数（CV）分别为1.69％～6.98％和6.49％～10.27％.B-CLL患者APRIL mRNA及蛋白表达水平均显著高于健康对照（均P＜0.05）,各期组间比较差异均有统计学意义（均P＜0.05）,有治疗指征组mRNA及蛋白表达水平均高于无治疗指征组（P＜0.05）.结论 APRIL可能参与B-CLL的发生、发展并与其分期密切相关,且可能成为预测疾病进展的有效因子及治疗靶点.
Objective To quantitatively analyze the mRNA and protein expression level of a proliferation-inducing ligand （APRIL） and investigate its clinical significance in peripheral blood mononuclear cells and plasma from newly diagnosed patients with B-cell chronic lymphocytic leukemia （B-CLL）.Methods The mRNA of the target gene in 32 B-CLL patients and 15 health controls was quantified with real-time fluorescence quantitative polymerase chain reaction （RFQ-PCR） and protein by enzyme-linked immunosorbent assay （ELISA）.Results APRIL mRNA was assayed with RFQ-PCR,the intra-and inter-batch reproducibility showed the coefficient of variation （CV） were 1.69 %-6.98 % and 6.49 %-10.27 %,respectively.The expressions of APRIL mRNA and protein in patients with B-CLL were significantly higher than those in control （P 〈 0.05）,and significant difference was noted among the comparable stages in the arms （P 〈 0.05）.The expression of APRIL mRNA and protein in TDI （treatment-demand-indicator） arm was significantly higher than those in non-TDI arm （P 〈 0.05）.Conclusions APRIL may be involved in the formation and development of B-CLL and be an influence factor for disease staging.Thus,APRIL may be a prognostic indicator as well as the therapy target for the disease.
出处
《白血病．淋巴瘤》
CAS
2014年第3期156-159,共4页
Journal of Leukemia & Lymphoma
关键词
白血病
B细胞
慢性
增殖诱导配体
预测因子
Leukemia,B-cell,chronic
A proliferation-inducing ligand
Prognostic indicator
